A new analogue less affected by p-gp is annamycin (ANN), an anthracycline antibiotic with high affinity for lipid membranes and significantly more activity than doxorubicin (DOX). We investigated whether ANN was affected by pgp-mediated multidrug resistance (MDR) by comparing the cellular accumulation and retention of ANN, idarubicin (IDR), and DOX in the p-gp-negative human leukemia cell lines (HL-60s) and its DOX-selected p-gp-positive subline (HL-601 DOX) with and without verapamil (VERI. As expected, HL-60/DOX cells showed lower DOX uptake than HL-60s cells; coincubation with VER (10 mmol/L) increased uptake 2.6-fold, restoring it to100% of uptake in HL-60s cells. IDR uptake increased 1.5-fold in the presence of VER, but ANN was not affected. Coincubation with VER increased DOX retention in HL-GO/DOX cells 2.8-fold and IDR retention 1.4-fold;
D been shown to be mediated by multiple molecular mechanisms, is a major problem in chemotherapy.' Despite the fact that 80% to 90% of patients with adult acute myeloid or lymphoid leukemia respond to intensive chemotherapy, more than 50% of the patients relapse, often because the recurrence of disease is associated with clinical drug resistance.' One well-characterized mechanism of multidrug resistance (MDR) is an energy-dependent transport system for such natural-product cytotoxic drugs as anthracycline antibiotics, vinca alkaloids, epipodophyllotoxins, and dactinom y~i n .~ This mechanism of action is often related to overexpression of the 170-kD membrane p-glycoprotein (p-gp) : and the cellular pharmacological consequence of MDR seems to be reduced accumulation of drugs.5 Recently p-gp was shown not to be a pump itself but a regulator for the activity of an endogenous volume-activated chloride channeL6 The gene (MDR1) for p-gp has been cloned, sequenced, and located on human chromosome 7.' Transfection with MDRl cDNA confers the MDR phenotype on drug-sensitive cells.' To overcome this type of resistance, agents that block p-gp have been used in chemotherapy. Verapamil (VER), a calcium channel blocker, was the first agent shown to reverse MDR in several resistant cell lines by interfering with p-gp function,' but many other p-gp-blocking agents have been identified." In these in vitro" and in vivo'2,'3 systems, MDR is overcome by increased intracellular accumulation of cytotoxic drugs.14 Because intrinsic and acquired drug resistance remains a major problem in cancer, great interest has been generated by studies showing that a variety of agents can successfully overcome resistance in MDRl -positive ~e1ls.I~ This has led to clinical trials of combinations of chemotherapy and p-gp blockers. Although some studies have shown positive results,I6-" the p-gp blockers' toxicity has aroused controversies regarding their clinical use. Moreover, their evaluation is further complicated by the multifactorial nature of drug-resistance mechanisms.
Another potentially effective way to circumvent the MDR . . The amino group, known to be a common structural feature of various chemotherapeutic drugs that show crossresistance in p-gp-positive cells,29 also determines the affinity of anthracyclines for negatively charged phospholipids, including cardiolipin.'"," ANN has been shown to be significantly more active than DOX in several in vitro"." and in vivo tumor models including L-1210 leukemid' and subcutaneous B-16 tumor." Unlike DOX, ANN was also found to be capable of inducing different types of DNA lesions and drug-induced apoptosis in resistant cells." Recently, ANN was shown to be effective in treating KB-VI xenografts in vivo.'" Phase I clinical studies with ANN formulated in a liposomal carrier in solid tumors have just been started at The M.D. Anderson Cancer Center. In this study. we compared the cellular pharmacology of ANN and IDR with that of DOX, because both IDR and ANN have been shown to overcome MDRl partially in different systems. We studied uptake and retention in the presence of VER using laser flow cytometry to quantitate intracellular anthracycline content in the p-gp-negative human myeloid leukemia cell line (HLdOS) and its DOX-derived p-gp-positive cell line (HL-60mOX). We also performed cytotoxicity assays to determine whether increased intracellular content of anthracycline was associated with increased cytotoxicity. Finally, to better understand the cellular pharmacology and distribution of anthracyclines, we studied the different intracellular distribution patterns using confocal laser microscopy (CLM) with available optical sectioning. The results of these experiments suggested that, in our system, 
167-

120-
-MDRl -62-M
ANN more
was effective in overcoming p-gp-related MDR and efficient than IDR and DOX in circumventing it.
MATERIALS AND METHODS
ANN was synthesized and purified as described prev i o u~l y .~~ Free ANN was suspended in 10% dimethyl sulfoxide and 90% normal saline ( I mg/mL of stock solution). The final dimethyl sulfoxide concentration was 0.05% for an ANN concentration of 5 mg/mL. DOX (Cetus Corp, Emeryville, CA) and IDR (Adria Laboratories, Columbus, OH) were dissolved in sterile water. All anthracyclines were diluted with RPMI 1640 containing 10% fetal calf serum (FCS) before each experiment. VER (Sigma Chemical Co, St Louis, becco's medium (GIBCO-BRL) supplemented with 10% FCS, I% penicillin, 1 % streptomycin, and 1 % L-glutamine. Cell cultures were maintained at 37°C in a humified atmosphere of 5% C02/95% air.
RNA extraction and reverse transcriptase-polymerase chain reaction (RT-PCR). RNA was isolated according to the acid-guanidium-phenol-chloroform method.'* RT-PCR was performed as previously reported." Briefly, 1 p g of total RNA was used for cDNA production with a cDNA synthesis kit (Boehringer Mannheim, Indianapolis, IN); 1/10 of the reaction was used for the PCR. The MDRl and P2-microglobulin genes were amplified simultaneously in different aliquots. The PCR (total volume, 25 pL) contained 1 mmol/L of each primer, 1.25 U of Taq-polymerase, 2.5 pL of 1OX PCR buffer (Perkin Elmer-Cetus, Norwalk, CT), 0.2 pL of 25-mmol deoxynucleotide triphosphate, and 2 pCi of 32P-deoxycytidine triphosphate (Dupont, Wilmington, DE). Each cycle included a denaturation step at 94°C for 30 seconds, an annealing step at 63°C for 30 seconds, and an elongation step at 72°C for 45 seconds. Twenty-eight cycles were performed, followed by a final extension at 72°C for 10 minutes using a PCR processor (Model 9600; Perkin Elmer-Cetus). PCR products (3 pL) were analyzed through 8% polyacrylamide gel (BioRad, Richmond, CA). Electrophoresis was performed at 300 V for 3.5 hours. 32P-incorporation was quantitated to Betascope 603 (Betagen, Waltham, MA) and subsequently exposed for 8 hours at -70" C to a Kodak X-Omat film (Eastman-Kodak, Rochester, NY) without an intensification screen.
For the study of p-gp, monoclonal antibody (MoAb) 4E3 (generously supplied by Dr R. Arceci, Dana-Farber Cancer Center, Boston, MA) was used as follows: 2 X IO6 cells/ tube in 100 pL of phosphate-buffered saline (PBS), without Ca2+ or Mg2' (Sigma) and containing a 1:l dilution of human serum with PBS, were incubated into Falcon tubes (Becton Dickinson, San Jose, CA) at 4°C for 30 minutes to inhibit nonspecific binding of antibodies to Fc receptors. PBS (2 mL) was then added to the cells, which were collected by centrifugation at 6008 for 5 minutes. Pelleted cells were resuspended in 100 pL of PBS containing 1% bovine serum albumin and 10 pg/mL of the anti-p-gp MoAb or isotype-matched nonreactive controls. This mixture was incubated for 30 minutes at 4°C; then, cells were washed twice with cold PBS and resuspended in 100 pL of PBS containing 1% bovine serum albumin and a secondary antibody fluorescein isothiocyanate (F1TC)-conjugated goat-antimouse Igs (Becton Dickinson). Cells were incubated with the second antibody for 30 minutes at 4°C in the dark and then washed twice in cold PBS.
Flow cytometric analysis was done with a FAC-SCAN flow cytometer (Becton Dickinson) equipped with an argon ion laser (Spectra Physics, Mountain View, CA) operating at 488 nm and 15 mW. Light was collected through 585/42 band-pass filters for anthracycline uptake and retention studies and a 530-130-nm filter (FITC) for 4E3 MoAb detection. Data acquisition and analysis were performed with the Lysys I1 software (Becton Dickinson). Forward and side scatter signal were collected using a linear scale, and fluorescence signals were collected on a logarithmic scale. Kolmogorov-Smimov analysis of data was performed, and the results are expressed as D-values2 Cells were incubated at the concentration of 2 x 106/mL in medium plus 5% FCS with or without VER (10 pmollL) for 2 hours at 37°C with ANN, IDR, or DOX at the concentration of 5 pg/mL. For uptake studies, aliquots of 5 x lo5 cells were obtained after 15, 30,60,90, and 120 minutes of incubation. Cells were washed in ice-cold PBS without Caz+ or Mg2+ (Sigma) and resuspended in 0.5 mL of ice-cold PBS, and anthracycline fluorescence was measured within 5 minutes. For retention studies, at the end of 2 hours of exposure, every sample was washed twice in ice-cold PBS and resuspended for 2 hours in fresh medium with or without VER, at the same concentration used for uptake studies. Cells were incubated at 37°C. and aliquots of cells
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were analyzed at 15, 30, 60, 90, and 120 minutes, under the same conditions as those used for uptake studies. Each experiment was performed in triplicate, and representative experiments are shown in Figs 4 and 5. Increased uptake and retention were calculated by dividing the median level of fluorescence after 2 hours of incubation with VER by the fluorescent signal of the drug alone measured at the same time point. The level of increase was calculated after correcting each value for autofluorescence of the blank and is expressed as the mean of three experiments. Similar experiments were also conducted using CyA (5 mg/mL) and PSC833 (1 mg/mL) as p-gp blockers. HL-60s and HL-60DOX cells were plated in 96-microwell plates and incubated at 37°C overnight. Cultures were exposed to various concentrations of DOX, IDR, and ANN at 37°C for 4 hours; the drugs were removed; the cells were rinsed 3 times with Ca'+-and Mg2'-free PBS (pH, 7.4) and were recultured in drug-free fresh medium for 3 days. Cell survival was determined with reduction of 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as described by Hansen et
The IDIo value was calculated by extrapolating from the graphic results the drug concentration that causes a 50% cell death.
We used a Zeiss (New York, NY) confocal laser scanning microscope, upright version with LSMv2.0 software, equipped with an external Argon laser (488 nm, I O mW). Signals were collected by a photomultiplier after passing a 540/20 band-pass filter. Digitized images were transmitted to an Macintosh-based image analysis system through a general purpose interface board (GPIB) interface using BDS-LSM software (Biological Detection Systems, Pittsburgh PA). For image processing, we used IPLdb software (Signal Analytics, Vienna, VA). Teflon-coated glass microscopy slides (Cel-line Associates, Newfield, NJ) with 10 wells (each 7 mm in diameter and containing 10 mL) were used. Cells adhering to the microscope slide were analyzed for ANN, IDR, and DOX distribution under oilimmersion microscopy. HL-60s and HL-60DOX were incubated in presence of ANN, IDR, and DOX either with or without VER as described above for uptake studies. Drug distribution was recorded within 5 minutes after 30 and 90 minutes of incubation with the drugs. The images showed the distribution of anthracycline fluorescence after confocal sectioning of interphase cells. Figure 4 shows uptake and retention of ANN (Fig 4A) and IDR (Fig 4B) compared with those of DOX in HL-601DOX cells exposed to 5 pglmL of anthracyches either alone or in combination with 10 pmoY L of VER. Incubation with DOX resulted in minimal drug uptake that increased 2.5-fold in the presence of VER. Uptake of ANN (Fig 4A) was faster than that of DOX and similar to that of IDR (Fig 4B) , with the plateau phase having already been reached at the first measurement and with no uptake increase being observed in the presence of VER. After 2 hours of incubation in the continuous presence of different anthracyclines, cells were washed twice in cold medium and reincubated for 2 hours in fresh medium at 37°C with or without VER. HLdO/DOX cells showed a decrease in intracellular concentration of DOX that was almost completely reversed by VER. The HL-60DOX retention of DOX was increased 2.8-fold by VER. No change in the intracellular content of ANN was observed in presence of VER during the retention studies. As shown in Fig 4B , the curve for IDR was similar to that of ANN, with rapid achievement of the plateau phase and a stable level of intracellular drug concentration during the 2 hour-incubation with the drug. Incubation with VER increased IDR uptake and retention 1.5-and 1.4-fold, respectively. CyA and PSC 833 were assayed under the same experimental conditions for their ability to increase anthracycline uptake and retention in HL-60DOX cells, and their efficacy was compared with that of VER. Results shown in Table 1 showed a similar efficacy for the three p-gp blockers at the concentration used. The rapid drop in ANN and IDR fluorescence levels observed within the first few minutes of efflux was mainly determined by the washing steps required for removing the drug from the medium after the uptake studies (data not shown). This phenomenon was observed in both HL-60/DOX and HL-60 cells, and we believe it may be related to higher ANN and IDR lipophilicity and affinity for external cytoplasmic membrane.
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Cellular uptake and retention of anthracyclines in HL60s and effect of VER. Figure 5 shows the uptake and retention studies of ANN (Fig 5A) and IDR (Fig 5B) compared with those of DOX in HL-60s as described above. Again, IDR and ANN uptakes were faster than DOX uptake. Cells were then washed twice and reincubated in fresh medium for the efflux studies, as described above, and resuspended in fresh medium. In HL-60S, no DOX efflux was For personal use only. on October 27, 2017. by guest www.bloodjournal.org From Cytotoxicity was determined after 4-hour exposure of cells to different concentration of drugs, using the MTT assay as described in Materials and Methods. All data are mean -c SD of three independent experiments.
Values for IDw were determined from plot of cell survival fractions versus drug concentrations.
observed; the drug showed a constant intracellular level that was not modified by VER. A slow decrease in the intracellular concentration of both ANN and IDR observed in HL60s cells was also not modified by VER. This non-p-gp- related slow pattern of efflux is probably related to the higher lipophilicity of ANN and IDR.
Cellular accumulation in sensitive cells was higher than that in resistant cells; the resistance uptake factor, S / R (S/ R, the uptake by sensitive cells divided by uptake by resistant cells), was 1.03 for ANN, 1.9 for IDR, and 2.6 for DOX. Incubation with VER markedly reduced the S/R for IDR (from 1.9 without VER to 1.3 with VER) and for DOX (from 2.6 without VER to 1.02 with VER). No changes were observed for ANN (1.03 without VER and 1.04 with VER; see Table 2 ).
In vitro cytotoxicity against HL-60s and HLdO/DOX. Results of the cytotoxicity studies with ANN, IDR, and DOX with or without VER against HL-60s and HL-60DOX cells are shown in Fig 6 and Table 3 . In these studies, cells were exposed to different concentrations of the agents for 4 hours, and cytotoxicity was determined by an MTT assay after a 72-hour incubation period. In HL-60S, IDR was about 100 times more cytotoxic than ANN (IDSo, 0.004 2 0.003 v 0.30 t 0.17, respectively) and 10 times more cytotoxic than DOX (IDso, 0.004 2 0.003 v 0.078 2 0.003, respectively). How- for HL-60/DOX) and DOX required a 117-fold increase in concentration to reach the ID5" (IDso, 0.078 t 0.003 for HL60s v 9.13 2 0.55 for HL-60/DOX). In accordance with these results, the calculated resistance index (RI; IDso HL-60DOX/IDso HL-60s) was 2.6 for ANN, 40 for IDR, and 117.5 for DOX. We also evaluated cytotoxicity in the presence of VER to learn whether an increase in intracellular drug content was associated with increased cytotoxicity. In HL-60/DOX cells, incubation with VER increased the cytotoxicity of DOX and IDR, with a 6.2-fold reduction of IDso for DOX (IDso. 1. Intracellular anthracycline distribution in HL-60s and HLdO/DOX as determined by CLM. After 30 minutes, HL60s cells incubated in the presence of DOX showed a pattern of DOX-related fluorescence predominantly in the cytoplasm and perinuclear regions (Fig 7A) . After 90 minutes, an increased distribution of the drug was observed within the nucleus (Fig 7B) . This intracellular distribution was not modified by the presence of VER (Figs 7C and D) . In HL-601 DOX cells, DOX uptake was limited mainly to the intracytoplasmic region after 30 minutes, and the fluorescence intensity was lower than that in HL-60s cells (Fig 8A) . No 
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further increase was noted after 90 minutes (Fig 8B) . In these cells, incubation of DOX in the presence of VER resulted in a consistent increase of DOX-related fluorescence after 30 and 90 minutes (Figs 8C and D) , with the drug distributed mainly within intracytoplasmic structures. In contrast to DOX, no significant changes were observed for IDR and ANN when sensitive and resistant cell lines were compared with or without VER. No differences were noted during the different time points (data not shown), probably indicating a faster uptake and intracellular distribution related to higher IDR and ANN lipophilicity. IDR-related fluorescence (Fig  9) was distributed mainly in the cytoplasmic region, the perinuclear zone, and nuclear membrane (Fig 9A) . The intracellular distribution was similar in HLdOS ( Fig 9A) and HLdO/DOX cells (Fig 9C) , and only a small increase in IDR fluorescence was noted in HL-60/DOX cells when incubated in the presence of VER (Figs 9C and D) . Subcellular distribution of ANN (Fig 10) was observed mainly in the cellular membrane and cytoplasm region. The pattern was similar for the two cell lines and was not influenced by VER.
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DISCUSSION
The main objective of our study was to assess the ability of the new anthracycline ANN to overcome MDRl in a human leukemia cell line and to compare it with IDR and DOX, which are widely used in front-line protocols for treating patients with acute leukemia. For that purpose, we compared the cellular pharmacology and in vitro cytotoxicity of the three agents against HLdOS and HL-60DOX cells in the presence and absence of the resistance-modifier VER. Although the total intracellular concentration of each anthracycline could not be directely compared by flow cytometry and CML, because of each drug's different fluorescent emission pattern, our results indicated the following:
(1) The intracellular accumulation of ANN is similar in sensitive and resistant cells (S/R index, 1.03), whereas the cellular accumulation of DOX and IDR is lower in resistant than in sensitive cells. The difference was more pronounced for DOX ( S / R index, 2.6) than for IDR (SIR index, 1.9). It is noteworthy that measurement of the anthracycline's relative fluorescence level by flow cytometry or microscopy may not represent precisely the total amount of drug in cell compartments because fluorescence is partially quenched, especially in the nucleu~.~"' However, we assumed that these phenomena take place to the same relative extent in both sensitive and resistant cells4' and should not influence evaluation of the SA3 index.
(2) For each drug we found that differences in cellular drug accumulation and cytotoxicity correlated between the two cell lines; ANN showed almost unimpaired cytotoxicity against resistant cells (RI, 2.6), whereas the resistance indices for IDR and DOX were 40 and 117, respectively. Previous studies showed anthracycline fluorescence to correlate well with extemal,J' intracellular?4 (measured by extraction methods), and cytotoxic As in our results, however, the relationship was not always linear. We believe that the divergence may be related to differences in subcellular drug localization.32 Higher drug concentration may first saturate the nonmatrix compartment and then lead to increased affinity for the nuclear matrix where DNA synthesis occurs. Simultaneous action of alternative mechanisms of resistance is another possible explanation: however, when we tested HL-60s and HL-60/DOX, we observed no differences in expression of the MDR-associated protein 4h and the M, I10,OOO protein." (pl IO) recognized by MoAb LRP-56 (data not shown). Recently, we suggested that expression of genes related to the bcl-2 family in HL-60 is altered during development of anthracycline chemoresistance,4X which implicates multiple distinct mechanisms acting at various points to confer cell resistance to chemotherapy.
(3) VER affected neither ANN'S cellular accumulation nor cytotoxicity against resistant cells (no change in RI and S/R index), whereas VER restored almost completely the cellular accumulation of IDR and DOX in resistant cells, with a corresponding, although modest, decrease in the RI. This effect was greater for DOX than for IDR (4-fold reduction in RI for DOX versus 2-fold for IDA). Similar results have been obtained with other MDRl cell lines selected for resistance to DOX "." or vinblastine""' in studies comparing ANN and DOX. None of the p-gp modulators tested significantly increased the accumulation or retention of ANN For personal use only. on October 27, 2017. by guest www.bloodjournal.org From in either HL-60DOX or KB-Vl. 49 Taken together, the results of this and previous studies strongly indicate that ANN may overcome p-gp-mediated resistance and that it is a potentially effective agent for treatment of human neoplasms, such as acute leukemia, malignant lymphoma, or breast carcinoma, in which expression of the MDRl phenotype may be a clinically relevant mechanism of constitutive or acquired r e s i s t a n~e .~~~~'
As we have said, the data suggested that additional mechanisms of resistance may be involved in the HL-60DOX cell line. Although the same fluorescence levels were achieved for DOX and IDR in HLdOS and HLdO/DOX cells by using VER and for ANN even without VER, MDR was not completely circumvented. ANN was much more effective than DOX or IDR in overcoming resistance (Table 3) . Therefore, ANN seemed to overcome such non-MDR1 mechanisms more efficiently than DOX or IDR. Ling et a13' have shown that DOX localizes predominantly in the nucleus of KB-3-1 cells, in contrast to ANN, which locates preferentially in the perinuclear region, Golgi apparatus, endoplastic reticulum, and endosomes. However, Ling et a13* also showed by cell fractionation that nuclear ANN tends to localize preferentially in the nuclear matrix, unlike DOX, which distributes preferentially in the nonmatrix. Because topoisomerase (topo 11) locates mainly in the nuclear matrix, and top0 11-mediated mechanisms of anthracycline resistance have been described, ANN may be able to overcome such top0 11-mediated mechanisms of resistance as a result of its different subnuclear distribution.
ANN differs from DOX at four positions in its chemical structure: (1) substitution at C-2' with iodine, (2) hydroxylation at C-3', (3) epimerization at C-4, and (4) demethoxylation at C-4'. Previous studies showed that the replacement of the basic amino group at C-3' by a hydroxyl is one of the primary reasons for ANN'S high in vivo and in vitro activity against MDRl t~m o r s . '~~'~~~~ Information regarding the contribution of 4-demethoxylation at C-4 on the biological properties of this class of compounds can be derived from this study because we compared ANN and DOX with IDR (4-demethoxydaunorubicin). IDR, which is currently approved for the treatment of acute leukemia, differs from DOX not only at position C-4 (4-demethoxylation) but also at C-14 (14-hydrogen versus 14-hydroxy). The lower RI and lower resistance uptake factor (S/R) of IDR, compared with those of DOX, can most likely be attributed to the 4-demethoxylation, because the 14-hydroxy modification that distinguishes DOX and DNR has not been consistently reported to confer those properties.22~s2 This indicates that 4-demethoxylation might also contribute to ANN'S ability to partially overcome MDRl and suggests that ANN may be useful in treating DOX-resistant leukemias.
